Omega-3 fatty acids — specifically DHA and EPA — have been studied as a possible risk-reduction factor for postpartum depression, and the honest summary is: the evidence is real but inconsistent, and weaker than it first looks. Some meta-analyses find an average reduction in depressive symptoms. Several well-controlled individual trials find no effect at all. And the subgroup findings most often quoted as "it works best after birth" mostly did not reach statistical significance in the analysis they come from. No study shows omega-3 supplementation treats, cures, or reliably prevents postpartum depression, and no responsible reading of this research supports using a supplement in place of screening or care from a doctor or mental health professional. What follows is what the trials actually measured — the encouraging findings and the null results both — plus what's known about omega-3 safety during pregnancy and breastfeeding, and what to do if you or someone you know is struggling right now.
What the research actually shows
The idea that omega-3 fatty acids might matter for postpartum mood didn't start with a clinical trial — it started with an observation. A widely cited cross-national analysis compared seafood consumption and the DHA content of breast milk across dozens of countries and found that higher fish/DHA intake tracked with lower reported rates of postpartum depression.1 That's an ecological correlation, not proof of cause and effect — diet, culture, healthcare access, and reporting all differ across countries too — but it's the observation that motivated the controlled trials that followed.
Those trials give a genuinely mixed picture, which is worth sitting with rather than smoothing over. A 2020 meta-analysis in Translational Psychiatry pooled 8 placebo-controlled randomized trials (638 women) and found a moderate overall effect of omega-3 monotherapy on perinatal depressive symptoms (SMD 0.65, 95% CI 0.10–1.20, p=0.02) — but with very high heterogeneity between studies (I²=91%), which means the trials disagreed with each other a great deal and the pooled average is a shakier summary than the number alone suggests.2 Its subgroup analyses found benefit in both pregnancy (SMD 0.46, 95% CI 0.01–0.91, p=0.05) and postpartum (SMD 1.59, 95% CI 0.65–2.53, p<0.001), the larger estimate being postpartum. On EPA content, the picture is thinner than usually reported: in formulas with an EPA:DHA ratio of 1.5 or higher the effect only approached significance (SMD 0.52, 95% CI 0.00–1.04, p=0.05), and in lower-EPA formulas there was no effect at all (SMD −0.09, p=0.76). One more unflattering detail: benefit appeared in trials shorter than 8 weeks (SMD 0.84, p<0.0001) and not in trials of 8 weeks or longer (SMD 0.58, p=0.17).
A separate, larger 2020 meta-analysis in the Journal of Clinical Psychiatry pooled 18 randomized trials (4,052 women) and found a small but significant overall benefit (SDM −0.236, 95% CI −0.463 to −0.009, p=.042), with considerable heterogeneity (I²=88.6%).3 It then broke the effect down by timing — and this is where the popular summary goes wrong. The postpartum estimates were larger in magnitude but not statistically significant: postpartum women SDM −0.656 (95% CI −1.690 to 0.378, p=.214); trials specifically studying postpartum depression SDM −0.886 (95% CI −2.088 to 0.316, p=.149); already-depressed women SDM −0.545 (95% CI −1.182 to 0.093, p=.094). The pregnancy estimate was negligible (SDM −0.071). The authors' own clinical conclusion is worth quoting for what it recommends against: they "advise against prescribing omega-3 PUFAs for the treatment or prevention of depressive symptoms during pregnancy, given a lack of effect with low heterogeneity," while describing it as a possible add-on treatment for postpartum depression specifically.
Two meta-analyses found a small average benefit. The postpartum subgroup estimates that get quoted as the headline mostly did not reach significance — and the largest individual trials found nothing at all.
Against that, two of the more rigorously controlled individual trials found no effect. The Mothers, Omega-3, and Mental Health Study (MOMS) randomized 126 pregnant women already at increased risk of depression — an Edinburgh Postnatal Depression Scale score of 9–19 or a history of depression — to EPA-rich fish oil (1,060mg EPA plus 274mg DHA), DHA-rich fish oil (900mg DHA plus 180mg EPA), or soy oil placebo; 118 completed.4 There were no differences between groups in Beck Depression Inventory scores or other depression endpoints at any of the three post-supplementation time points, during pregnancy or after, even though blood levels confirmed the supplements were absorbed. The authors' conclusion was unambiguous: EPA-rich and DHA-rich fish oil supplementation did not prevent depressive symptoms during pregnancy or postpartum. A Brazilian trial of 60 women at risk of postpartum depression gave 1.8g/day of combined EPA+DHA (1.08g EPA, 0.72g DHA) from weeks 22–24 of gestation for 16 weeks and found the same null result: no difference in the prevalence of an EPDS score of 11 or higher, in EPDS scores over time, or in change in EPDS scores, in either intention-to-treat or per-protocol analysis.5 A subgroup of women with a prior history of depression did show a significantly greater reduction in symptom scores (LME β=−3.441, 95% CI −6.532 to −0.350, p=0.029) — a result the study's own authors flagged as needing further, dedicated research rather than treated as confirmed.
Why the studies disagree
A few real differences likely explain the split, rather than one set of trials being simply "wrong." Dose and EPA:DHA ratio varied a lot between trials, and higher-EPA formulas performed somewhat better — though, as above, only to the edge of statistical significance. Timing may matter: point estimates were larger for postpartum-targeted supplementation than for pregnancy-only use in both meta-analyses, even where those postpartum estimates weren't individually significant, and the pregnancy-only evidence is consistent enough in showing nothing that one review's authors recommend against it outright. Baseline risk may matter too — women with an existing depression history showed larger effects in both a subgroup analysis and one individual trial, again without reaching significance in the pooled data. And trial duration cuts against the intuitive story: in the Translational Psychiatry analysis the benefit appeared in shorter trials, not longer ones. None of this adds up to a confirmed protocol; it's a set of open questions the current evidence points toward, not settled clinical guidance. The broader omega-3-and-mood literature has the same shape, as our review of omega-3 and depression sets out — and for a nutrient with a comparably thin evidence base handled the same way, see zinc and depression.
What this does — and doesn't — mean for you
It means omega-3/DHA supplementation has been studied as a possible adjunct or risk-reduction factor for postpartum depression, with real but inconsistent trial support — point estimates largest for postpartum-targeted use, effectively nil for pregnancy-only use, and nowhere near strong enough to be called prevention or treatment on its own. It does not mean a fish oil supplement is a substitute for screening, therapy, or medication, and none of the trials above tested it as a replacement for those. If you're already working with a doctor or therapist on postpartum depression, omega-3 intake is a reasonable thing to mention as one factor among many — not a reason to delay or skip evaluation and care. For interventions with a stronger evidence base for depressive symptoms generally, the exercise trial data is a more substantial place to start.
A note on dose, and what our label actually is
The trials above used 1.2g to 1.8g a day of combined EPA and DHA — and mostly found nothing. Proco's Omega-3 provides 180mg EPA and 120mg DHA per softgel; at the label's suggested use of one softgel twice daily, that's 600mg of combined EPA and DHA a day, well below the amounts these perinatal trials tested. We are not going to describe our serving as the studied dose, because it isn't, and in a topic this serious the gap matters more than usual. Our EPA/DHA dosage guide works through what different intakes correspond to, and the blood-thinner interaction question is worth reading if that applies to you.
Pregnancy and breastfeeding: safety, and what our label actually says
Separately from the depression research, omega-3/DHA is one of the more reassuringly studied supplements for use during pregnancy and lactation as a general matter — DHA supports fetal brain and eye development, and the NIH's Office of Dietary Supplements notes adequate omega-3 intake is part of standard prenatal nutrition guidance.6 The main safety caution from NIH's National Center for Complementary and Integrative Health is about mercury from whole fish, not purified fish oil supplements specifically, and it's a food-sourcing issue more than a supplement one; the same guidance is clear that anyone using a complementary supplement during pregnancy should talk with their healthcare provider about it.7
Proco's Omega-3 (180mg EPA + 120mg DHA per serving) doesn't carry pregnancy- or breastfeeding-specific instructions on its physical label — the label's suggested use is one softgel twice daily as a general adult dose, with the standard "keep out of reach of children" and FDA supplement disclaimers. We don't want to imply otherwise. Our own product-page guidance is that omega-3 has a comparatively well-supported safety profile in pregnancy and breastfeeding, but that's still not the same as a green light without a conversation — particularly because prenatal vitamins often already contain DHA, and you don't want to unintentionally double up your total intake.8 Confirm with your OB-GYN, midwife, or doctor before adding this or any new supplement during pregnancy or while breastfeeding — bring your full supplement list, including your prenatal, to that conversation. Our range-wide pregnancy and breastfeeding guidance covers which products carry which cautions.
Bottom line
Omega-3/DHA supplementation has real, published research behind it as a possible risk-reduction factor for postpartum depression — two meta-analyses show a small significant average benefit — but the heterogeneity is very high, the postpartum subgroup estimates that get quoted as the headline mostly didn't reach significance, one review's authors explicitly advise against prescribing it during pregnancy, and the best-controlled individual trials found no effect. Treat it as one small, uncertain factor to discuss with your doctor, never as a substitute for postpartum depression screening, therapy, or medication. If you're pregnant or breastfeeding, confirm any new supplement — including this one — with your OB-GYN or doctor first. And if you're struggling right now, please reach out: to your doctor, to a mental health professional, or, if you're in crisis, to 988 or emergency services immediately. If brain fog rather than mood is what's bothering you most, postpartum brain fog covers a separate and better-characterised phenomenon.
References
- Hibbeln JR. "Seafood consumption, the DHA content of mothers' milk and prevalence rates of postpartum depression: a cross-national, ecological analysis." Journal of Affective Disorders, 2002. pubmed.ncbi.nlm.nih.gov
- Zhang MM, Zou Y, Li SM, et al. "The efficacy and safety of omega-3 fatty acids on depressive symptoms in perinatal women: a meta-analysis of randomized placebo-controlled trials." Translational Psychiatry, 2020;10:193. nature.com
- Mocking RJT, Steijn K, Roos C, et al. "Omega-3 Fatty Acid Supplementation for Perinatal Depression: A Meta-Analysis." Journal of Clinical Psychiatry, 2020;81(5):19r13106. pubmed.ncbi.nlm.nih.gov
- Mozurkewich EL, et al. "The Mothers, Omega-3, and Mental Health Study: a double-blind, randomized controlled trial." American Journal of Obstetrics and Gynecology, 2013;208(4):313.e1–9. pubmed.ncbi.nlm.nih.gov
- Vaz JDS, Farias DR, Adegboye ARA, Nardi AE, Kac G. "Omega-3 supplementation from pregnancy to postpartum to prevent depressive symptoms: a randomized placebo-controlled trial." BMC Pregnancy and Childbirth, 2017;17:180. pubmed.ncbi.nlm.nih.gov
- "Omega-3 Fatty Acids." NIH Office of Dietary Supplements, Consumer Fact Sheet. ods.od.nih.gov
- "Omega-3 Supplements: What You Need To Know." NIH National Center for Complementary and Integrative Health. nccih.nih.gov
- Proco Omega-3 EPA 180mg + DHA 120mg, product label and description. procohq.com
This article is for informational purposes only and has not been evaluated by the FDA. It is not intended to diagnose, treat, cure, or prevent any disease. Speak with a healthcare provider before starting any new supplement, especially if you take medication, are pregnant or breastfeeding, or have an existing health condition. Postpartum depression is a serious, treatable clinical condition — this article is not a substitute for screening, diagnosis, or care from a qualified doctor or mental health professional. If you are having thoughts of harming yourself or your baby, contact emergency services or a crisis line (988 in the US) immediately.
Want to know what's actually in what you take? Join the list — no spam, just it straight.